Results 71 to 80 of about 165,634 (303)

Desmosomal Antigens Are Not Recognized by the Majority of Pemphigus Autoimmune Sera [PDF]

open access: yes, 1983
Sera from 7 patient with pemphigus vulgaris and both mouse and rabbit antisera against bovine epidermal desmosomes contained antibodies that bound to cell surface components of the spinous layer of bovine epidermis.
Gorbsky, Gary   +2 more
core   +2 more sources

Serum angiotensin converting enzyme in pemphigus vulgaris

open access: yesIndian Journal of Dermatology, 2014
Background: Pemphigus vulgaris is an autoimmune blistering skin disease with unknown etiology. Drugs such as angiotensin-converting enzyme (ACE) inhibitors may contribute in the pathogenesis of pemphigus.
Reza M Robati   +3 more
doaj   +1 more source

Utility of IgG4 immunohistochemistry detection in pemphigus diagnosis

open access: yesSAGE Open Medical Case Reports, 2022
Pemphigus includes a group of blistering autoimmune diseases that affect the skin and mucosa, characterized by the formation of epidermal bullous and the presence of antibodies against binding proteins.
Maricela García-Lechuga   +4 more
doaj   +1 more source

Rituximab as the treatment of pemphigus vulgaris in the COVID‐19 pandemic era: A narrative review

open access: yesDermatologic Therapy, 2020
Pemphigus vulgaris (PV), an autoimmune blistering disease is treated with immunosuppressive medications. As the immunosuppressive effect of rituximab, the first‐line therapy of PV, lasts more than 6 months, many concerns have raised due to the ongoing ...
Amir Mohammad Beyzaee   +3 more
semanticscholar   +1 more source

The role of nitric oxide synthases in pemphigus vulgaris in a mouse model [PDF]

open access: yes, 2008
Pemphigus vulgaris (PV) is a blistering autoimmune disease characterized by IgG autoantibodies against desmoglein 3. Nitric oxide synthases (NOS) may contribute to the increase of inflammation in tissues by the generation of ...
España, A. (Agustín)   +3 more
core   +1 more source

Validation of the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus

open access: yesJournal of the European Academy of Dermatology and Venereology, 2020
The BIOCHIP is a novel multiplex indirect immunofluorescence technique used in the serological diagnosis of bullous pemphigoid and pemphigus. The BIOCHIP method combines the screening of autoantibodies and target antigen‐specific substrates in a single ...
Anes Yang   +4 more
semanticscholar   +1 more source

Endemic Pemphigus Vulgaris [PDF]

open access: yesArchives of Dermatology, 2007
Investigators from Brasilia, Brazil, observed several patients with a mucocutaneous disease that resembles pemphigus vulgaris clinically and histologically but with epidemiological features of fogo selvagem. Our objective was to characterize antidesmoglein 3 and antidesmoglein 1 autoantibody profiles in these unique patients who reside in Goiânia and ...
Rosicler, Rocha-Alvarez   +8 more
openaire   +2 more sources

Paraneoplastic pemphigus with clinical features of lichen planus associated with low-grade B cell lymphoma [PDF]

open access: yes, 2005
BACKGROUND: Neoplasia-induced lichen planus is described as a cell-mediated reaction to unknown epithelial antigens. Paraneoplastic pemphigus (PNP), characterized by the presence of a specific array of autoantibodies, probably represents a different form
Black, M   +4 more
core   +1 more source

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

open access: yesBritish Journal of Dermatology, 2019
Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid‐related adverse events (AEs) is unproven.
D. Chen   +41 more
semanticscholar   +1 more source

Case Report: Apremilast for Therapy-Resistant Pemphigus Vulgaris

open access: yesFrontiers in Immunology, 2020
Background In pemphigus, elucidating the disease-causing immune mechanism and developing new therapeutic strategies are needed. In this context, the second messenger 3′,5′-cyclic adenosine monophosphate (cAMP) is gaining attention.
K. Meier   +4 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy